Optibrium provides innovative in silico platforms and AI solutions that increase the speed, efficiency, and productivity of chemistry discovery programs. Self-described as transforming drug discovery.

Optibrium

Software Development

StarDrop

Optibrium | 8,422 followers on LinkedIn. elegant software that guides successful drug discovery
 | Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process.

Health and life sciences CEO, Chair and Non-Executive Director. Professor of Practice, Kings College London.

Andy Black

Vice President of Research, BioPharmics Division, Optibrium

Ajay Jain

Ann Cleves Jain

CEO at Optibrium Ltd

Matthew Segall

I’m getting ready to head to day 2 of the #SLASDataAI Symposium. Yesterday’s talks and posters reminded me that, although we’re each researching one specific area, the applications of data science and AI/ML in drug discovery are diverse - image analysis, autonomous robots, LLMs, prediction of compounds and their properties, and the infrastructure to support it all. Derek Lowe (In the Pipeline blog) urged us in his keynote to remember that we should consider not only what an AI/ML model can tell us, but what it can’t say is at least as important. Today you can find me at poster 6 presenting our research into AI-guided idea generation. SLAS (Society for Laboratory Automation and Screening)

Tamsin Mansley

Want to develop advanced multi-parameter optimisation strategies and target the right compounds, faster? Join Edmund Champness as he demonstrates how to build scoring profiles using historical data and analyse the sensitivity of your decisions to the criteria you choose. Register at https://lnkd.in/eS3aAkPD Learn how you can take a more fine-tuned, targeted approach to optimisation to accelerate your discovery and swiftly pinpoint better compounds. This webinar follows on from July’s popular ‘Finding balance in drug discovery with multi-parameter optimisation’ event. Whether you were with us last time, or are just keen for new MPO insights, this webinar is for anyone who wants to: ✔️Avoid being led astray by poor quality, mixed source data ✔️Be confident in their compound selection criteria ✔️Understand the best approaches to MPO in any given scenario ✔️Work through live examples of MPO done right, using StarDrop’s MPO Explorer software

How do generative chemistry methods work, and how can they help you? Michael Parker discusses the common models used for generative chemistry and the best way to apply these in his new blog. If you're interested in traditional vs AI methods, diffusion and sequence models, or realistic expectations of what generative chemistry AI can achieve, have a read. 👉 https://lnkd.in/eZi-USbW

I’m enjoying the excellent science with Anthony Nicholls and colleagues at the OpenEye, Cadence Molecular Sciences MiniCUP in Boston today. This morning Geoff Skillman gave a fascinating talk about 3D QSAR and I’m looking forward to learning about advances in Antibody Theraputics (Jesper Sorensen), Design of Experiment ( Gregory Bakken ), faster Virtual Screening ( Matthew• Geballe ), Crystal Structure Prediction ( Jeff Grandy ), Cryptic Pocket Detection ( David LeBard ) and more. It’s impressive that OpenEye can provide solutions for all these diverse drug discovery challenges. The view of downtown Boston from the Museum of Science is pretty nice too!

Just one week to go until Ajay Jain and Ann Cleves Jain share their molecular docking expertise in our webinar. Join us by registering at https://lnkd.in/eXYwuWfz And learn how we can... ...automate complex preparation, alignment, selection, and preparation for docking ...predict the binding modes of future ligands, using a temporal case study where target structures used for docking were determined prior to those of the ligands being docked ...use non-macrocyclic complexes to predict the binding modes of macrocyclic ligands See you there! 👋

Want to accelerate your drug discovery with collaborative design? StarDrop's Idea Tracker can help. Find out more at https://lnkd.in/ei7Wm_ir

Missed our webinar on deep learning for peptide property and bioactivity prediction? Catch up with the results of our scientific collaboration with MSD , on demand on our website: https://lnkd.in/evguTQFw The webinar featured detailed scientific presentations from Samar Mahmoud , an introduction to Cerella from Matthew Segall , and an insightful Q&A session with Dan Sindhikara . If you're interested in predictive modelling, peptide drug discovery or AI-guided decision making, this is one to revisit.

Want to explore the chemistry space around your hit or lead compound? StarDrop offers several ways of generating virtual libraries - join Alessia Centi and Tamsin Mansley for Open Training in November to explore our library enumeration methods. Whether you're a current StarDrop user who wants to follow along with practical examples and get your questions answered, or a drug hunter looking to get a view of StarDrop's enumeration capabilities, this training is for you. Register now at https://lnkd.in/ep6brFwA

Interested in predicting drug metabolism, but don't know which software is right for you? Scott McDonald has outlined some of the key benefits and methodology behind different commercially available platforms, to help you make your decisions. Read the article: https://lnkd.in/epuw4C6M

Matthew Segall and Nathan Cable are at the Oxford Global Discovery US congress in Boston next week, where they'll be presenting on 'overcoming drug metabolism challenges using mechanistic in silico models', and on 'data imputation to augment R&D and enhance your decision-making'. If you'll be at the event, please let us know - we'd love to discuss how your research, and how it could benefit from such methods. Interested in the conference, but not yet registered? Delegate passes for research organisations with a therapeutic research pipeline are free - find out more about the event and register at https://lnkd.in/erGzffye .

Metric
Company Name	Optibrium
Symbol
MSH ID	COM:OPTIBRIUM
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	UK
Stage	Private Equity Round
Employee Count
Website	optibrium.com
LinkedIn	optibrium-ltd-
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.14K
Web Traffic Growth	0.03
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

OPTI

COM:OPTIBRIUM

Optibrium

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue